Matthew W. McClure - Apr 27, 2022 Form 3 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Medical Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Matthew W. McClure
Stock symbol
ALGS
Transactions as of
Apr 27, 2022
Transactions value $
$0
Form type
3
Date filed
5/6/2022, 04:12 PM
Next filing
Jul 11, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ALGS Common Stock 91.2K Apr 27, 2022 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALGS Stock Option (Right to Buy) Apr 27, 2022 Common Stock 53.6K $3.45 Direct F2
holding ALGS Stock Option (Right to Buy) Apr 27, 2022 Common Stock 256K $16.18 Direct F3
holding ALGS Stock Option (Right to Buy) Apr 27, 2022 Common Stock 92K $3.06 Direct F4
holding ALGS Stock Option (Right to Buy) Apr 27, 2022 Common Stock 23K $3.06 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Matthew Wright McClure and Elizabeth Maureen McClure Revocable Trust.
F2 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 20, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F3 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F5 100% of the shares subject to the option will be fully vested and exercisable on February 4, 2025.